Cargando…

Emerging dynamics pathways of response and resistance to PD-1 and CTLA-4 blockade: tackling uncertainty by confronting complexity

Immune checkpoint inhibitors provide considerable therapeutic benefit in a range of solid cancers as well as in a subgroup of hematological malignancies. Response rates are however suboptimal, and despite considerable efforts, predicting response to immune checkpoint inhibitors ahead of their admini...

Descripción completa

Detalles Bibliográficos
Autores principales:	Relecom, Allan, Merhi, Maysaloun, Inchakalody, Varghese, Uddin, Shahab, Rinchai, Darawan, Bedognetti, Davide, Dermime, Said
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2021
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7893879/ https://www.ncbi.nlm.nih.gov/pubmed/33602280 http://dx.doi.org/10.1186/s13046-021-01872-3

Ejemplares similares

Unleashing the immune response to NY-ESO-1 cancer testis antigen as a potential target for cancer immunotherapy
por: Raza, Afsheen, et al.
Publicado: (2020)

Role of Epstein–Barr Virus in the Pathogenesis of Head and Neck Cancers and Its Potential as an Immunotherapeutic Target
por: Fernandes, Queenie, et al.
Publicado: (2018)

CAR-cell therapy in the era of solid tumor treatment: current challenges and emerging therapeutic advances
por: Maalej, Karama Makni, et al.
Publicado: (2023)

Squamous Cell Carcinomas of the Head and Neck Cancer Response to Programmed Cell Death Protein-1 Targeting and Differential Expression of Immunological Markers: A Case Report
por: Merhi, Maysaloun, et al.
Publicado: (2018)

Persistent anti-NY-ESO-1-specific T cells and expression of differential biomarkers in a patient with metastatic gastric cancer benefiting from combined radioimmunotherapy treatment: a case report
por: Merhi, Maysaloun, et al.
Publicado: (2020)

Editorial: Dynamic Biomarkers of Response to Anti-Immune Checkpoint Inhibitors in Cancer
por: Dermime, Said, et al.
Publicado: (2021)

Treatment with decitabine induces the expression of stemness markers, PD-L1 and NY-ESO-1 in colorectal cancer: potential for combined chemoimmunotherapy
por: Taib, Nassiba, et al.
Publicado: (2023)

Circulating exosomal immuno-oncological checkpoints and cytokines are potential biomarkers to monitor tumor response to anti-PD-1/PD-L1 therapy in non-small cell lung cancer patients
por: Akbar, Shayista, et al.
Publicado: (2023)

Role of Non Receptor Tyrosine Kinases in Hematological Malignances and its Targeting by Natural Products
por: Siveen, Kodappully S., et al.
Publicado: (2018)

Dynamic liquid biopsy components as predictive and prognostic biomarkers in colorectal cancer
por: Raza, Afsheen, et al.
Publicado: (2022)

Guggulsterone Induces Apoptosis in Multiple Myeloma Cells by Targeting High Mobility Group Box 1 via Janus Activated Kinase/Signal Transducer and Activator of Transcription Pathway
por: Akhtar, Sabah, et al.
Publicado: (2022)

Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis, therapeutics and vaccines
por: Fernandes, Queenie, et al.
Publicado: (2022)

Curcumin Induces Apoptotic Cell Death via Inhibition of PI3-Kinase/AKT Pathway in B-Precursor Acute Lymphoblastic Leukemia
por: Kuttikrishnan, Shilpa, et al.
Publicado: (2019)

Evaluation of cationic channel TRPV2 as a novel biomarker and therapeutic target in Leukemia-Implications concerning the resolution of pulmonary inflammation
por: Siveen, Kodappully S., et al.
Publicado: (2019)

CTLA-4 and PD-1 Pathway Blockade: Combinations in the Clinic
por: Callahan, Margaret K., et al.
Publicado: (2015)

Serum immune mediators as novel predictors of response to anti-PD-1/PD-L1 therapy in non-small cell lung cancer patients with high tissue-PD-L1 expression
por: Raza, Afsheen, et al.
Publicado: (2023)

Targeting of X-linked inhibitor of apoptosis protein and PI3-kinase/AKT signaling by embelin suppresses growth of leukemic cells
por: Prabhu, Kirti S., et al.
Publicado: (2017)

Greensporone C, a Freshwater Fungal Secondary Metabolite Induces Mitochondrial-Mediated Apoptotic Cell Death in Leukemic Cell Lines
por: Prabhu, Kirti S., et al.
Publicado: (2018)

Tackling COVID-19 pandemic through nanocoatings: Confront and exactitude
por: Rai, Pradeep Kumar, et al.
Publicado: (2020)

Greensporone A, a Fungal Secondary Metabolite Suppressed Constitutively Activated AKT via ROS Generation and Induced Apoptosis in Leukemic Cell Lines
por: Prabhu, Kirti S., et al.
Publicado: (2019)

Impact of prophylactic TNF blockade in the dual PD-1 and CTLA-4 immunotherapy efficacy and toxicity
por: Alvarez, Maite, et al.
Publicado: (2019)

Antimesothelioma Immunotherapy by CTLA-4 Blockade Depends on Active PD1-Based TWIST1 Vaccination
por: Tan, Zhiwu, et al.
Publicado: (2020)

Confronting Uncertainty in Wildlife Management: Performance of Grizzly Bear Management
por: Artelle, Kyle A., et al.
Publicado: (2013)

A novel series of conferences tackling the hurdles confronting the translation of novel cancer immunotherapies
por: Bot, Adrian, et al.
Publicado: (2012)

Sanguinarine Induces Apoptosis Pathway in Multiple Myeloma Cell Lines via Inhibition of the JaK2/STAT3 Signaling
por: Akhtar, Sabah, et al.
Publicado: (2019)

Distinct immunological mechanisms of CTLA-4 and PD-1 blockade revealed by analyzing TCR usage in blood lymphocytes
por: Robert, Lidia, et al.
Publicado: (2014)

Interleukin-21 combined with PD-1 or CTLA-4 blockade enhances antitumor immunity in mouse tumor models
por: Lewis, Katherine E., et al.
Publicado: (2017)

Small vessel vasculitis and dry gangrene secondary to combined CTLA-4 and PD-1 blockade in malignant mesothelioma
por: Kefas, Joanna, et al.
Publicado: (2022)

Reprogramming Intrahepatic Cholangiocarcinoma Immune Microenvironment by Chemotherapy and CTLA-4 Blockade Enhances Anti-PD1 Therapy
por: Chen, Jiang, et al.
Publicado: (2023)

The introduction of LAG-3 checkpoint blockade in melanoma: immunotherapy landscape beyond PD-1 and CTLA-4 inhibition
por: Kreidieh, Firas Y., et al.
Publicado: (2023)

CTLA-4 blockade: therapeutic potential in cancer treatments
por: Tarhini, Ahmad A, et al.
Publicado: (2010)

BloodGen3Module: blood transcriptional module repertoire analysis and visualization using R
por: Rinchai, Darawan, et al.
Publicado: (2021)

Confronting a Paradox: A New Perspective of the Impact of Uncertainty in Suspense
por: Delatorre, Pablo, et al.
Publicado: (2018)

Tackling the 3 Big Challenges Confronting Health Technology Assessment Development in Asia: A Commentary
por: Teerawattananon, Yot, et al.
Publicado: (2020)

Synergistic Reversal of Intrahepatic HCV-Specific CD8 T Cell Exhaustion by Combined PD-1/CTLA-4 Blockade
por: Nakamoto, Nobuhiro, et al.
Publicado: (2009)

Distinct Dynamics of Migratory Response to PD-1 and CTLA-4 Blockade Reveals New Mechanistic Insights for Potential T-Cell Reinvigoration following Immune Checkpoint Blockade
por: Safaeifard, Fateme, et al.
Publicado: (2022)

PD-1/CTLA-4 Blockade Leads to Expansion of CD8(+)PD-1(int) TILs and Results in Tumor Remission in Experimental Liver Cancer
por: Bufe, Sandra, et al.
Publicado: (2022)

Activated CTLA‐4‐independent immunosuppression of Treg cells disturbs CTLA‐4 blockade‐mediated antitumor immunity
por: Watanabe, Tomofumi, et al.
Publicado: (2023)

Protective Immunity to Nematode Infection Is Induced by CTLA-4 Blockade
por: McCoy, Kathy, et al.
Publicado: (1997)

CTLA-4 blockade synergizes with cryoablation to mediate tumor rejection
por: Waitz, Rebecca, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_p9h6re6eociflcq3830fsbij4s